U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07492927) titled 'Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer' on March 19.

Brief Summary: The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Study Start Date: March 12, 2021

Study Type: OBSERVATIONAL

Condition: Clinically Significant Prostate Cancer

Recruitment Status: RECRUITING

Sponsor: Xijing Hospital

Published by HT Digital Content Services with permission from Health Daily Digest....